CTNM Stock Summary and Trading Ideas (Contineum Therapeutics | NASDAQ:CTNM)

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.

As of October 16, 2026, CTNM stock price declined to $7.08 with 1,063,936 million shares trading.

CTNM has a beta of 1.13, meaning it tends to be more sensitive to market movements. CTNM has a correlation of 0.02 to the broad based SPY ETF.

CTNM has a market cap of $266.36 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

CTNM has underperformed the market in the last year with a price return of -43.2% while the SPY ETF gained +16.7%. CTNM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.5% and -46.0%, respectively, while the SPY returned +1.9% and -0.8%, respectively.

CTNM support price is $7.43 and resistance is $8.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.